On July 30th and 31st, the Third Oriental Congress of Molecular Diagnostics SSMD 2021 opened at the Shanghai International Convention Centre. This academic conference focuses on the development and applications of cutting-edge molecular diagnostics technologies in the field of cancer, infectious diseases, pharmacogenomics, and genetic diseases.
On the day of the 31st, the Septin9 DNA Methylation Seminar with Dr. F. Sun from The NO.10 People’s Hospital of Shanghai, Tongji University, and hosted by Dr. Y. Hou from Zhongshan Hospital, Fudan University, successfully provided a better, easier and faster method for colorectal cancer detection.
Dr. Sun shared incredible insights by summarizing the status quo and characteristics of colorectal cancer, pointing out the patient compliance of colorectal cancer detection, and sharing the case studies of septin9 DNA methylation, which gained wide public entrust and compliment.
The Status Quo and Characteristics of Colorectal Cancer Paroxysm:
International database shows that Colorectal Cancer (CRC) has a high incidence rate, while the death rate keeps climbing and showing a trend of getting youthful. According to the latest data released by China’s cancer centre, the incidence of colorectal cancer is 12.2%, second only to lung cancer and breast cancer, with a mortality rate of 9.5%, all of which is higher than the world level.
The early symptoms of colorectal cancer are not obvious, and the development process is slow, which is easy to be ignored. About 80% of patients in China are in the advanced stage at the time of diagnosis. Compared with the early patients, the five-year survival rate of patients in the advanced stage is only 10.4%. The prevention of colorectal cancer brooks no delay.
How to Improve the Compliance of Colorectal Cancer Detection in Chinese Population
Early screening and detection are important means to prevent colorectal cancer. At present, the common colorectal cancer screening methods mainly include colonoscopy and fecal occult blood test.
Colonoscopy is the gold standard for the diagnosis of colorectal cancer and the recommended screening method for high-risk groups. However, colonoscopy has a relatively low sensitivity to progressive adenomas and early colorectal cancer. The detection rate of lesions is affected by many factors, including intestinal preparation, colonoscopy operation, and the level of endoscopist. In addition, colonoscopy is invasive with a poor patient compliance. Fecal occult blood test is one of the commonly used non-invasive detection methods for colorectal cancer, but its sensitivity needs to be further improved.
To improve the participation rate and compliance of colorectal cancer detection, a simpler and more convenient colorectal cancer detection method is urgently needed in clinical practices. Accurate and effective stratification examination of the population and colonoscopy in a fully concentrated high-risk population are crowd examination strategies that are more in line with the national conditions of China. In recent years, with the development of molecular diagnostic techniques such as PCR, methylation detection of Septin9 gene in plasma came into being. According to the latest “China Experts Consensus on Experimental Diagnosis Technology of Early Colorectal Cancer and Precancerous Lesions in 2021”, blood Septin9 methylation detection has the advantages of non-invasive, convenient sampling and high patient acceptance, making it the first choice for subjects.
Application Value of Detection of Methylation of Plasma Septin9
Methylated Septin9 gene is a specific molecular marker in the early occurrence and development of colorectal cancer, which is of great significance to improve patients’ detection compliance. It was written into the guidelines for the diagnosis and treatment of early colorectal cancer screening in China in 2014. Septin9 gene is related to apoptosis and division of cells. The methylation of Septin9 gene will lead to abnormal cell division and cancer, which will be released into the blood in the forms of apoptosis and necrosis. Detection of methylated SEPTIN9 gene fragments in blood can be used for the early diagnosis of CRC.
Detection of Methylation of S9 Gene – A New Method of the Diagnosis of Colorectal Cancer
Tellgen Coporation’s ColonS9 DNA methylation detection kit (hereinafter referred to as Colon S9, registration certificate No.: Guoxie Zhuquasi 20193400316) is based on sulfide modification technique and Taqman probe real-time PCR platform. This kit can realize the specific detection of methylated Septin9 gene in plasma samples and is suitable for clinical auxiliary diagnosis of colorectal tumors. Relevant clinical research data shows that the total coincidence rate of Colon S9 and DNA methylation sequencing methods is 99.81%. In addition, based on the gold standard for clinical diagnosis, its sensitivity is up to about 70% and specificity is higher than 94%, while in patients with colorectal cancer, its sensitivity is up to 100% and specificity is 99.45%.
The methylation detection of Colon S9 gene of Tellgen has the following three characteristics:
- Non-invasive–venous blood collection, highest adherence test sample, non-invasive, non-painful, no need for pre-preparation;
- Simple—The sample collection is simple, convenient, uniform and stable, the sampling is easy to standardize, and the detection is convenient;
- Convenience–The common real-time PCR technology can be developed in two channels, FAM and CY5.
Colorectal cancer is currently recognized worldwide as a malignant tumor that can reduce the mortality rate through the existing effective means of intervention. China has a large population, and medical resources are scarce and distributed unevenly. In addition, the current situation of colorectal cancer is grim in recent years. Plasma Septin9 gene methylation detection is a non-invasive, simple, and highly acceptable new method for early detection of colorectal cancer. It is an accurate and effective stratification method for concentrating high-risk groups, a crowd detection strategy that is more in line with China’s national conditions, and conducive to improving the participation rate and compliance of colorectal cancer detection in China.